Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Gaiser, Maria [VerfasserIn]   i
 Bongiorno, Michelle [VerfasserIn]   i
 Brownell, Isaac [VerfasserIn]   i
Titel:PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma
Verf.angabe:Maria Rita Gaiser, Michelle Bongiorno, Isaac Brownell
E-Jahr:2018
Jahr:14 Mar 2018
Umfang:15 S.
Fussnoten:Gesehen am 08.08.2019
Titel Quelle:Enthalten in: Expert review of clinical pharmacology
Ort Quelle:London : Informa Healthcare, 2008
Jahr Quelle:2018
Band/Heft Quelle:11(2018), 4, Seite 345-359
ISSN Quelle:1751-2441
Abstract:Introduction: Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer that lacks durable responses to traditional chemotherapy.Areas covered: After MCC was shown to be an immunogenic tumor, small trials revealed high objective response rates to PD-1/PD-L1 checkpoint inhibitors. The JAVELIN Merkel 200 (NCT02155647) trial tested the use of avelumab, a human IgG1 monoclonal antibody against PD-L1, in metastatic MCC. Avelumab recently became the first approved drug for metastatic MCC.Expert commentary: By conducting broad phase I studies assessing the safety of avelumab and a small phase II study demonstrating efficacy in this rare orphan tumor type, avelumab gained accelerated approval for the treatment of metastatic MCC. Additional studies are needed to determine how the antibody-dependent cellular cytotoxicity (ADCC) competent Fc region of avelumab contributes to disease control.Remaining questions: Longer follow-up will determine the durability of checkpoint blockade in controlling metastatic MCC. Additional studies will assess the utility and safety of adjuvant checkpoint blockade in patients with excised MCC. How to increase response rates by combining PD-1/PD-L1 blockade with other treatment approaches needs to be explored. In addition, treatment options for MCC patients who fail or do not respond to avelumab need to be identified.
DOI:doi:10.1080/17512433.2018.1445966
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1080/17512433.2018.1445966
 DOI: https://doi.org/10.1080/17512433.2018.1445966
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Anti-PD-1
 anti-PD-L1
 avelumab
 Bavencio
 checkpoint inhibitor
 immunotherapy
 Merkel cell carcinoma
 pembrolizumab
K10plus-PPN:1671028872
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68419150   QR-Code
zum Seitenanfang